SZU General Hospital

Qiang Li
SZU General Hospital
Internal Medicine (Endocrinology)
Professor, Chief Physician
简介:


BIOGRAPHICAL SKETCH


NAME: Qiang LI


POSITION TITLE: Professor, Chief Physician


EDUCATION/TRAINING

INSTITUTION AND LOCATION

DEGREE

COMLETION DATE

FIELD OF STUDY

Bethune Medical University, Changchun

Bachelor

1987

Medicine

Harbin Medical University, Harbin

Master

1994

Internal Medicine (Endocrinology)

Fudan University, Shanghai

Doctor

 

2006

Internal Medicine (Endocrinology)

 

A. Personal statement

 

B. Positions and honors

Positions

1987-1994 Physician, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

1994-1997 Attending Physician, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

1997-2000 Associate Professor, Deputy Chief Physician, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

2000-2018 Professor, Chief Physician, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

2018-present Professor, Chief Physician, Shenzhen University General Hospital, Shenzhen, China

Honors

2015, Award of Heilongjiang Provincial Science and Technology Progress, Harbin, 9th position

2004, Award of Heilongjiang Provincial Science and Technology Progress, Harbin, 1st position

2001, Award of Heilongjiang Provincial Science and Technology Progress, Harbin, 2nd position 

1996, Award of Heilongjiang Provincial Science and Technology Progress, Harbin, 2nd position

C. Representative publications (selected publications in recent five years   5-10篇)

1.Nationally edited textbook "Internal Medicine" (for undergraduates), editorial board, People's Medical Publishing House, Beijing, July 2018

2.Nationally edited textbook "Diagnosis" (for the starting point of junior college for undergraduate), associate editor, People's Medical Publishing House, Beijing, March 2019

3.National unified textbook "Internal Medicine" (8-year and 7-year system), editorial board, People's Medical Publishing House, Beijing, September 2015

4.Nationally edited textbook "Endocrinology Section of Internal Medicine" (for standardized training of residents), editorial board, People's Medical Publishing House, Beijing, October 2015

5.Endocrine Society of Chinese Medical Association, Author, Chinese consensus on prevention and treatment of type 2 diabetes with dyslipidemia (2017 revision), Chinese Journal of Endocrinology and Metabolism 2017, 33 (11): 925-936

6.Glucagon-like peptide-1 contributes to increases ABCA1 expression by downregulating miR-758 to regulate cholesterol homeostasis. Biochemical and Biophysical Research Communications. 2018;497(2):652-697. Corresponding Author.

7.Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1.Cell Physiol Biochem 2018;50(2):679-693. Corresponding Author. 

8.Glucagon-like peptide-1 improves β-cell dysfunction by suppressing the miR-27a-induced downregulation of ATP-binding cassette transporter A1.Biomedicine & Pharmacotherapy 2017;96:497-502. Corresponding Author. 

9.Glucagon-like peptide-1 effects lipotoxic oxidative stress by regulating the expression of microRNAs.Biochemical and Biophysical Research Communications 2017;482(2):1462-1468. Corresponding Author.

10.GLP-1 contributes to increases in PGC-1a expression by downregulating miR-23a to reduce apoptosis.Biochemical and Biophysical Research Communications 2015;466(1):33-39. Corresponding Author. 

 

D. Research support

Ongoing projects (RMB)

Shenzhen University Technology Talent Promotion Program (Number:SUGH2018QD008)                                          

01/01/2018 to 12/31/2020

Qiang LI, PI                                                         ¥300,000